Telmisartan is an angiotensin receptor blocker (ARB) used alone or in combination with other agents for therapy of hypertension, in cardiac arrest, and in stroke management. Telmisartan was approved for use in the U.S., for treatment of hypertension in 1998. Telmisartan is available in 20, 40 and 80 mg tablets in generic forms and under the trade name, Micardis. The typical dose of Telmisartan in adults is 40 to 80 mg once daily, and it is used long term. Telmisartan is also available in fixed combinations with hydrochlorothiazide, and amlodipine.
Market Dynamics
Prevalence of high blood pressures, is increasing globally attributed to rising geriatric population, chronic disorders such as diabetes, and changing lifestyles which in turn is expected to increase the demand for telmisartan in global market. According to Blood Pressure UK, 2017 update, high blood pressure is the leading cause of heart disease and stroke, killing around 7.5 million people worldwide every year. In 1975, 594 million people were suffering from high blood pressure which increased to 1.1 billion in 2015 and is thought to be due to population growth and an aging population. Thus, rise in geriatric population suffering from high blood pressure is expected to be major factor for growth of telmisartan market in the forecast period.
Furthermore, increasing approvals for Abbreviated new Drug Application (ANDA) for manufacturing of generic telmisartan tablets is propelling growth of telmisartan in the global market. For instance, in July 2014, Glenmark Generics Inc., USA—a subsidiary of Glenmark Generics Limited—received ANDA approval from the U.S. Food and Drug Administration (USFDA) for telmisartan tablets.
Key features of the study:
- This report provides in-depth analysis of the telmisartan market, market size (US$ Mn) and cumulative annual growth rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017, as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global telmisartan market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include C.H. Boehringer Sohn AG & Ko. KG, Glenmark Generics Inc., Torrent Pharmaceuticals Ltd., Solco Healthcare U.S., Mylan Inc., Aurobindo Pharma Limited, Yichang Changjiang Pharmaceutical Co., Ltd, Wanbang Biopharmaceuticals, and Nippon Boehringer Ingelheim Co., Ltd.
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global telmisartan market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for telmisartan market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
- Global Telmisartan Market, By Strength:
- Global Telmisartan Market, By Indication:
- Hypertension
- Cardiac Arrest
- Stroke
- Global Telmisartan Market, By Composition:
- Global Telmisartan Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Telmisartan Market, By Region:
- North America
- By Country:
- Global Telmisartan Market, By Strength:
- Global Telmisartan Market, By Indication:
- Hypertension
- Cardiac Arrest
- Stroke
- Global Telmisartan Market, By Composition:
- Global Telmisartan Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Global Telmisartan Market, By Strength:
- Global Telmisartan Market, By Indication:
- Hypertension
- Cardiac Arrest
- Stroke
- Global Telmisartan Market, By Composition:
- Global Telmisartan Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Global Telmisartan Market, By Strength:
- Global Telmisartan Market, By Indication:
- Hypertension
- Cardiac Arrest
- Stroke
- Global Telmisartan Market, By Composition:
- Global Telmisartan Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Global Telmisartan Market, By Strength:
- Global Telmisartan Market, By Indication:
- Hypertension
- Cardiac Arrest
- Stroke
- Global Telmisartan Market, By Composition:
- Global Telmisartan Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- Global Telmisartan Market, By Strength:
- Global Telmisartan Market, By Indication:
- Hypertension
- Cardiac Arrest
- Stroke
- Global Telmisartan Market, By Composition:
- Global Telmisartan Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
- By Country:
- South Africa
- Central Africa
- North Africa
- Global Telmisartan Market, By Strength:
- Global Telmisartan Market, By Indication:
- Hypertension
- Cardiac Arrest
- Stroke
- Global Telmisartan Market, By Composition:
- Global Telmisartan Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Company Profiles
- C.H. Boehringer Sohn AG & Ko. KG *
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Glenmark Generics Inc.
- Torrent Pharmaceuticals Ltd.
- Solco Healthcare U.S.
- Aurobindo Pharma Limited
- Mylan Inc.
- Yichang Changjiang Pharmaceutical Co., Ltd
- Wanbang Biopharmaceuticals.
- Nippon Boehringer Ingelheim Co., Ltd.
“*” marked represents similar segmentation in other categories in the respective section.
